Avience Biomedicals IPO GMP: Grey Market Premium and Subscription on Day 2
- June 19, 2026
- Posted by: Ankit Jaiswal
- Category: IPO
Avience Biomedicals IPO GMP on Day 2: an unofficial grey market premium of around ₹45 to ₹70 over the ₹208 band, which varies by tracker and changes daily. Issue size ₹30.24 crore on NSE SME.
The Avience Biomedicals IPO GMP is in focus as the issue moves through the second day of bidding. Avience Biomedicals is an NSE SME molecular diagnostics maker, and grey market interest has been positive as bidding continues into the second day. The grey market premium discussed below is an unofficial figure that varies by source and changes daily, so treat it as sentiment only.
Click Here – Track Live IPO GMP and Get Free Investment Predictions
Avience Biomedicals IPO Details
Before looking at the Avience Biomedicals IPO GMP, here are the core terms of the issue. It is a book-built fresh issue on the NSE SME platform.
| Particulars | Details |
|---|---|
| Price Band | ₹196 to ₹208 |
| Lot Size | 600 shares |
| Minimum Investment (Retail) | ₹2,49,600 for 2 lots (1,200 shares) at the upper band |
| Issue Size | ₹30.24 crore (a 100 percent fresh issue of 14,53,800 shares) |
| Issue Type | Book-built fresh issue |
| Listing Platform | the NSE SME platform |
| Registrar | Skyline Financial Services |
3 Stocks Building Serious Momentum Right Now
When Univest analysts identify high-conviction stock opportunities, investors pay attention.
Our research team has now shortlisted the Top Stocks to Buy based on current market momentum, sector trends & growth potential.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks on Univest
Avience Biomedicals IPO GMP Today
In the latest available grey market updates, the Avience Biomedicals IPO GMP was reported at around ₹45 to ₹70 over the upper price band. If that premium were to hold, it would imply a listing price of around ₹253 to ₹278, an implied gain of roughly 22 to 34 percent over the ₹208 upper band. This is only an estimate. Grey market figures for this issue have varied across trackers and can move sharply before the shares actually list, so the real opening price will be set by demand on listing day.
Understanding the Grey Market Premium
The grey market premium is the price at which an IPO’s shares are unofficially traded before they list on the exchange. It is an unregulated indicator that is not recognised by SEBI or the stock exchanges, it is derived from market rumour and sentiment, and different trackers often quote different numbers for the same issue. For an SME IPO the grey market is thin, so even a few orders can swing the figure, and the premium can change from one day to the next. A grey market reading is therefore a sentiment signal at best and should never be the only reason to apply.
For the Avience Biomedicals IPO GMP, the more reliable signal is the subscription data during the bidding window. A strong premium that is backed by healthy subscription, especially from qualified institutional and non-institutional investors on the final day, is a more dependable indicator than a premium seen in isolation.
About Avience Biomedicals
Avience Biomedicals is an ISO-certified maker, supplier and exporter of molecular diagnostics and in-vitro diagnostics products, with a focus on biotechnology, genomics and laboratory solutions. Its range spans rapid test kits, biochemistry analysers and reagents, molecular diagnostics, hematology analysers and medical devices. The company operates mainly in business-to-business and business-to-government segments, also acts as a distributor and trader of medical equipment, and runs a manufacturing facility in Noida, Uttar Pradesh, serving pathology and microbiology labs, hospitals and research centres in India and abroad.
Avience Biomedicals Financials
Avience Biomedicals is a recently incorporated company, so its financial track record is short. Investors should study the financials and the risk factors in the offer document closely, as a limited operating history adds uncertainty for a diagnostics and medical-devices maker.
Avience Biomedicals IPO Strengths and Risks
Every IPO carries a mix of positives and risks. The main points investors weigh are below.
Strengths
- A diversified diagnostics and medical-devices range across kits, analysers and reagents.
- Exposure to a structurally growing in-vitro diagnostics and healthcare market.
- An export and institutional, business-to-government customer base.
Risks
- A very short operating history as a recently incorporated company.
- Reliance on imported components and a competitive diagnostics market.
- SME listing risks, a high minimum application size and a volatile grey market signal.
Check the Univest Screener to Research Listed Peers and Build Your Watchlist
Conclusion
The Avience Biomedicals IPO GMP captures only the unofficial mood around the issue, and as shown above it is a moving, unverified number. Avience Biomedicals is a young diagnostics and medical-devices maker in a structurally growing area, but its short operating history and SME risks call for caution. For any SME IPO, the high minimum application size, limited post-listing liquidity and price volatility mean the decision should rest on the business, valuation and use of proceeds rather than on grey market chatter. This article is educational, and investors should consult a SEBI-registered Investment Adviser before applying.
Download the Univest iOS App or Univest Android App to track live IPO grey market premium, subscription status and allotment updates.
Disclaimer: The information in this article is sourced from publicly available information, including exchange filings, the offer document and grey market trackers, and may or may not be accurate. Grey Market Premium (GMP) is an unofficial and unregulated indicator that is not endorsed by SEBI or the stock exchanges, varies across sources, and changes frequently. It is not a guarantee of the listing price or of any returns. SME IPOs carry a high degree of risk, limited liquidity and can be volatile after listing, and the high minimum application size makes them unsuitable for many investors. Please verify all figures with the official BSE (bseindia.com), NSE (nseindia.com) and the registrar before applying. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776). Investors should consult a SEBI-registered Investment Adviser before investing.
What is the Avience Biomedicals IPO GMP on Day 2?
Ans. In the latest available updates, the Avience Biomedicals IPO GMP was around ₹45 to ₹70 over the ₹208 upper band, implying a listing of roughly ₹253 to ₹278 if it holds. It is unofficial, varies by source and changes daily.
What is the Avience Biomedicals IPO price band and lot size?
Ans. The Avience Biomedicals IPO price band is ₹196 to ₹208 with a lot size of 600 shares. The minimum retail application works out to ₹2,49,600 for 2 lots (1,200 shares) at the upper band.
What is the issue size of the Avience Biomedicals IPO?
Ans. The Avience Biomedicals IPO is ₹30.24 crore (a 100 percent fresh issue of 14,53,800 shares), structured as a book-built fresh issue, and the shares are proposed to list on the NSE SME platform.
Does the Avience Biomedicals IPO GMP guarantee listing gains?
Ans. No. The Avience Biomedicals IPO GMP is an unofficial, unregulated indicator that is not endorsed by SEBI, varies across trackers and changes daily. It does not guarantee the listing price or any gains.
When will the Avience Biomedicals IPO list and on which platform?
Ans. The Avience Biomedicals IPO is proposed to list on the NSE SME platform on its listing day, after the basis of allotment is finalised once the bidding window closes. The exact schedule should be checked on the exchange and registrar websites.
Who is the registrar for the Avience Biomedicals IPO?
Ans. The registrar for the Avience Biomedicals IPO is Skyline Financial Services. Allotment status can be checked on the registrar’s website and on the NSE IPO page using a PAN or application number.
What are the risks of the Avience Biomedicals IPO?
Ans. The Avience Biomedicals IPO has a very short operating history, faces a competitive diagnostics market with reliance on imported components, and carries SME risks of low liquidity, volatility and a high minimum application size.
Is this Avience Biomedicals IPO GMP article investment advice?
Ans. No. This Avience Biomedicals IPO GMP article is educational content from Univest, a SEBI-registered Investment Adviser, and is not a recommendation to apply. Investors should consult a SEBI-registered Investment Adviser before investing.
